Powder: -20°C for 3 years | In solvent: -80°C for 1 year
RET-IN-22 (compound 17b) is a potent, selective, and orally active inhibitor of RET, exhibiting IC50 values of 20.9 nM for wild-type RET and 18.3 nM for RET-V804M. It demonstrates a highly selective inhibition profile across a broad spectrum of kinases, with notable specificity over EGFR and VEGFR2. Additionally, RET-IN-22 is implicated in exerting anticancer effects [1].
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約6-8 週間 | ¥ 349,000 |
50 mg | 約6-8 週間 | ¥ 454,500 |
100 mg | 約6-8 週間 | ¥ 574,000 |
説明 | RET-IN-22 (compound 17b) is a potent, selective, and orally active inhibitor of RET, exhibiting IC50 values of 20.9 nM for wild-type RET and 18.3 nM for RET-V804M. It demonstrates a highly selective inhibition profile across a broad spectrum of kinases, with notable specificity over EGFR and VEGFR2. Additionally, RET-IN-22 is implicated in exerting anticancer effects [1]. |
分子量 | 584.59 |
分子式 | C29H31F3N6O4 |
CAS No. | 2918281-79-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
RET-IN-22 2918281-79-3 Inhibitor inhibitor inhibit